BCRX Biocryst Pharmaceuticals Inc
Price (delayed)
$9.21
Market cap
$1.91B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.61
Enterprise value
$2.65B
BioCryst Pharmaceuticals discovers novel, oral, small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of
Highlights
BCRX's EPS has soared by 51% YoY and by 16% from the previous quarter
The net income has increased by 48% year-on-year and by 15% since the previous quarter
Biocryst Pharmaceuticals's quick ratio has decreased by 47% YoY
BCRX's equity is down by 14% year-on-year
Key stats
What are the main financial stats of BCRX
Market
Valuations
Earnings
Shares outstanding
207.13M
Market cap
$1.91B
Enterprise value
$2.65B
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
4.62
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
6.43
Revenue
$412.58M
Gross profit
$404.59M
Operating income
-$40.71M
Net income
-$123.82M
EBIT
-$25.48M
EBITDA
-$24.12M
Free cash flow
-$56.73M
Per share
Balance sheet
Liquidity
EPS
-$0.61
EPS diluted
-$0.61
Free cash flow per share
-$0.27
Book value per share
-$2.26
Revenue per share
$1.99
TBVPS
$2.37
Total assets
$491.25M
Total liabilities
$959.82M
Debt
$842.14M
Equity
-$468.56M
Working capital
$273.56M
Debt to equity
-1.8
Current ratio
2.78
Quick ratio
2.63
Net debt/EBITDA
-30.87
Margins
Efficiency
Dividend
EBITDA margin
-5.8%
Gross margin
98.1%
Net margin
-30%
Operating margin
-9.9%
Return on assets
-25.4%
Return on equity
N/A
Return on invested capital
-2.3%
Return on capital employed
-7.5%
Return on sales
-6.2%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
BCRX stock price
How has the Biocryst Pharmaceuticals stock price performed over time
Intraday
-1.92%
1 week
1.77%
1 month
21.02%
1 year
63.01%
YTD
22.47%
QTD
22.47%
Financial performance
How have Biocryst Pharmaceuticals's revenue and profit performed over time
Revenue
$412.58M
Gross profit
$404.59M
Operating income
-$40.71M
Net income
-$123.82M
Gross margin
98.1%
Net margin
-30%
The operating margin has soared by 71% YoY and by 37% from the previous quarter
BCRX's operating income has soared by 62% YoY and by 33% QoQ
BCRX's net margin has soared by 60% YoY and by 21% QoQ
The net income has increased by 48% year-on-year and by 15% since the previous quarter
Growth
What is Biocryst Pharmaceuticals's growth rate over time
Valuation
What is Biocryst Pharmaceuticals stock price valuation
P/E
N/A
P/B
N/A
P/S
4.62
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
6.43
BCRX's EPS has soared by 51% YoY and by 16% from the previous quarter
BCRX's equity is down by 14% year-on-year
The P/S is 71% lower than the 5-year quarterly average of 16.0 but 36% higher than the last 4 quarters average of 3.4
BCRX's revenue is up by 30% YoY and by 8% QoQ
Efficiency
How efficient is Biocryst Pharmaceuticals business performance
BCRX's ROS has soared by 84% YoY and by 48% from the previous quarter
The ROIC has soared by 81% YoY and by 44% QoQ
The company's return on assets rose by 43% YoY and by 14% QoQ
Dividends
What is BCRX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for BCRX.
Financial health
How did Biocryst Pharmaceuticals financials performed over time
Biocryst Pharmaceuticals's total assets is 49% lower than its total liabilities
Biocryst Pharmaceuticals's current ratio has decreased by 50% YoY
Biocryst Pharmaceuticals's quick ratio has decreased by 47% YoY
BCRX's equity is down by 14% year-on-year
BCRX's debt to equity is up by 13% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.